BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55-76. [PMID: 17295177 DOI: 10.1055/s-2006-960171] [Cited by in Crossref: 396] [Cited by in F6Publishing: 344] [Article Influence: 28.3] [Reference Citation Analysis]
Number Citing Articles
1 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
2 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
3 Mercer KE, Hennings L, Ronis MJ. Alcohol consumption, Wnt/β-catenin signaling, and hepatocarcinogenesis. Adv Exp Med Biol 2015;815:185-95. [PMID: 25427908 DOI: 10.1007/978-3-319-09614-8_11] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
4 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 248] [Article Influence: 30.3] [Reference Citation Analysis]
5 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
6 Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009;15:3210-6. [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
7 Chen T, Xiong J, Yang C, Shan L, Tan G, Yu L, Tan Y. Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth. Cancer Gene Ther 2014;21:133-8. [DOI: 10.1038/cgt.2014.8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
8 Hirai M, Kinugasa H, Nouso K, Yamamoto S, Terasawa H, Onishi Y, Oyama A, Adachi T, Wada N, Sakata M, Yasunaka T, Onishi H, Shiraha H, Takaki A, Okada H. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. J Gastroenterol Hepatol. 2020;. [PMID: 32830343 DOI: 10.1111/jgh.15227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation. 2007;75:843-852. [PMID: 17999742 DOI: 10.1111/j.1432-0436.2007.00235.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
10 Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol. 2008;26:2800-2805. [PMID: 18539957 DOI: 10.1200/jco.2007.15.5945] [Cited by in Crossref: 160] [Cited by in F6Publishing: 82] [Article Influence: 12.3] [Reference Citation Analysis]
11 Wang T, Gu J, Yuan J, Tao R, Li Y, Li S. Inferring pathway crosstalk networks using gene set co-expression signatures. Mol Biosyst 2013;9:1822-8. [PMID: 23591523 DOI: 10.1039/c3mb25506a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
12 Zhang XF, Tan X, Zeng G, Misse A, Singh S, Kim Y, Klaunig JE, Monga SP. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology 2010;52:954-65. [PMID: 20583210 DOI: 10.1002/hep.23747] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 5.7] [Reference Citation Analysis]
13 Cui J, Shen HM, Lim LHK. The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets. Pharmaceuticals (Basel) 2020;13:E432. [PMID: 33260729 DOI: 10.3390/ph13120432] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
14 Srivastava J, Siddiq A, Gredler R, Shen XN, Rajasekaran D, Robertson CL, Subler MA, Windle JJ, Dumur CI, Mukhopadhyay ND, Garcia D, Lai Z, Chen Y, Balaji U, Fisher PB, Sarkar D. Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice. Hepatology 2015;61:915-29. [PMID: 25065684 DOI: 10.1002/hep.27339] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
15 Lin WR, Lai MW, Yeh CT. Cyclin-dependent kinase-associated protein phosphatase is overexpressed in alcohol-related hepatocellular carcinoma and influences xenograft tumor growth. Oncol Rep 2013;29:903-10. [PMID: 23292002 DOI: 10.3892/or.2012.2208] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
16 Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res. 2010;108:21-72. [PMID: 21034965 DOI: 10.1016/b978-0-12-380888-2.00002-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 27] [Article Influence: 6.1] [Reference Citation Analysis]
17 Piguet AC, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C, St-Pierre MV, Dufour JF. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008;49:78-87. [PMID: 18486258 DOI: 10.1016/j.jhep.2008.03.024] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
18 Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up. Acta Radiol 2018;59:765-72. [DOI: 10.1177/0284185117732805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Yao N, Yao D, Wang L, Dong Z, Wu W, Qiu L, Yan X, Yu D, Chen J, Sai W. Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumour Biol. 2012;33:1767-1776. [PMID: 22684773 DOI: 10.1007/s13277-012-0436-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
20 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54. [PMID: 25153274 DOI: 10.1148/radiol.14132361] [Cited by in Crossref: 236] [Cited by in F6Publishing: 181] [Article Influence: 33.7] [Reference Citation Analysis]
21 Park S, Ha YN, Dezhbord M, Lee AR, Park ES, Park YK, Won J, Kim NY, Choo SY, Shin JJ, Ahn CH, Kim KH. Suppression of Hepatocyte Nuclear Factor 4 α by Long-term Infection of Hepatitis B Virus Contributes to Tumor Cell Proliferation. Int J Mol Sci 2020;21:E948. [PMID: 32023898 DOI: 10.3390/ijms21030948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 de Rosamel L, Blanc JF. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2017;22:175-90. [PMID: 28604110 DOI: 10.1080/14728214.2017.1336538] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
23 Abdel-Megeed RM, Abd El-Alim SH, Arafa AF, Matloub AA, Farrag AERH, Darwish AB, Abdel-Hamid AZ, Kadry MO. Crosslink among phosphatidylinositol-3 kinase/Akt, PTEN and STAT-5A signaling pathways post liposomal galactomannan hepatocellular carcinoma therapy. Toxicol Rep 2020;7:1531-41. [PMID: 33251120 DOI: 10.1016/j.toxrep.2020.10.018] [Reference Citation Analysis]
24 Kanda M, Murotani K, Sugimoto H, Miwa T, Umeda S, Suenaga M, Hayashi M, Hattori N, Tanaka C, Kobayashi D, Yamada S, Fujiwara M, Kodera Y. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget 2017;8:71070-9. [PMID: 29050343 DOI: 10.18632/oncotarget.20369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Amaya MJ, Nathanson MH. Calcium signaling in the liver. Compr Physiol 2013;3:515-39. [PMID: 23720295 DOI: 10.1002/cphy.c120013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
26 Kazmi I, Narooka AR, Afzal M, Singh R, Al-abbasi FA, Ahmad A, Anwar F. Anticancer effect of ursolic acid stearoyl glucoside in chemically induced hepatocellular carcinoma. J Physiol Biochem 2013;69:687-95. [DOI: 10.1007/s13105-013-0245-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
27 Sanchez-mejias A, Kwon J, Chew XH, Siemens A, Sohn HS, Jing G, Zhang B, Yang H, Tay Y. A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer: SOCS5/miR-18/miR-25 axis promotes tumorigenesis. Int J Cancer 2019;144:311-21. [DOI: 10.1002/ijc.31857] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
28 Modica TME, Dituri F, Mancarella S, Pisano C, Fabregat I, Giannelli G. Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC. Cancers (Basel) 2019;11:E1588. [PMID: 31635301 DOI: 10.3390/cancers11101588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol 2009;27:833-5. [PMID: 19139428 DOI: 10.1200/JCO.2008.19.1973] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
31 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
32 Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24. [PMID: 20228847 DOI: 10.1038/onc.2010.36] [Cited by in Crossref: 184] [Cited by in F6Publishing: 161] [Article Influence: 16.7] [Reference Citation Analysis]
33 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041-1053. [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
34 Freise C, Ruehl M, Erben U, Neumann U, Seehofer D, Kim KY, Trowitzsch-Kienast W, Stroh T, Zeitz M, Somasundaram R. A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Complement Altern Med. 2011;11:39. [PMID: 21569410 DOI: 10.1186/1472-6882-11-39] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
35 Liang B, Jia C, Huang Y, He H, Li J, Liao H, Liu X, Liu X, Bai X, Yang D. TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT. Dig Dis Sci 2015;60:2360-72. [PMID: 26025609 DOI: 10.1007/s10620-015-3730-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
36 Awuah PK, Rhieu BH, Singh S, Misse A, Monga SP. β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One. 2012;7:e39771. [PMID: 22761897 DOI: 10.1371/journal.pone.0039771] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
37 Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol 2008;26:5845-8. [PMID: 19029408 DOI: 10.1200/JCO.2008.19.7996] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
38 Shimizu M, Shirakami Y, Hanai T, Imai K, Suetsugu A, Takai K, Shiraki M, Moriwaki H. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids. Mol Nutr Food Res 2014;58:124-35. [PMID: 24273224 DOI: 10.1002/mnfr.201300538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
39 Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs. 2010;21:326-332. [PMID: 20016366 DOI: 10.1097/cad.0b013e3283350e26] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
40 Mimeault M, Batra SK. Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. Anticancer Agents Med Chem 2010;10:137-51. [PMID: 20184544 DOI: 10.2174/187152010790909353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
41 Zhang H, Chang WJ, Li XY, Zhang N, Kong JJ, Wang YF. Liver cancer stem cells are selectively enriched by low-dose cisplatin. Braz J Med Biol Res 2014;47:478-82. [PMID: 24770568 DOI: 10.1590/1414-431x20143415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
42 Li H, Zhang J, Lee MJ, Yu GR, Han X, Kim DG. OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways. Oncotarget 2017;8:18129-44. [PMID: 28184024 DOI: 10.18632/oncotarget.15185] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
43 Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, Silverstein KA, Sarver A, Starr TK, Akagi K, Tessarollo L, Collier LS, Powers S, Lowe SW, Jenkins NA, Copeland NG, Llovet JM, Largaespada DA. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009;27:264-74. [PMID: 19234449 DOI: 10.1038/nbt.1526] [Cited by in Crossref: 156] [Cited by in F6Publishing: 138] [Article Influence: 13.0] [Reference Citation Analysis]
44 Chong DQ, Tan IB, Choo SP, Toh HC. The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemp Clin Trials 2013;36:605-15. [PMID: 23591326 DOI: 10.1016/j.cct.2013.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
45 Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, Ramirez Morales R, Biasiolo A, Zanus G, Zali N. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer. 2014;110:2708-2715. [PMID: 24809782 DOI: 10.1038/bjc.2014.246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
46 Pontisso P. Role of SERPINB3 in hepatocellular carcinoma. Annals of Hepatology 2014;13:722-7. [DOI: 10.1016/s1665-2681(19)30974-3] [Cited by in Crossref: 21] [Article Influence: 3.0] [Reference Citation Analysis]
47 Louka ML, Fawzy AM, Naiem AM, Elseknedy MF, Abdelhalim AE, Abdelghany MA. Vitamin D and K signaling pathways in hepatocellular carcinoma. Gene 2017;629:108-16. [PMID: 28764978 DOI: 10.1016/j.gene.2017.07.074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
48 Marquardt JU, Fischer K, Baus K, Kashyap A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, Thorgeirsson SS, Galle PR, Strand S. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 2013;58:1054-64. [PMID: 23526469 DOI: 10.1002/hep.26413] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 11.8] [Reference Citation Analysis]
49 Zhang N, Wang L, Chai ZT, Zhu ZM, Zhu XD, Ma DN, Zhang QB, Zhao YM, Wang M, Ao JY, Ren ZG, Gao DM, Sun HC, Tang ZY. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling. PLoS One 2014;9:e115949. [PMID: 25542041 DOI: 10.1371/journal.pone.0115949] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
50 Baghy K, Tátrai P, Regős E, Kovalszky I. Proteoglycans in liver cancer. World J Gastroenterol 2016;22:379-93. [PMID: 26755884 DOI: 10.3748/wjg.v22.i1.379] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
51 Kudo M. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Dig Dis. 2011;29:273-277. [PMID: 21829017 DOI: 10.1159/000327558] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
52 Mercer KE, Hennings L, Sharma N, Lai K, Cleves MA, Wynne RA, Badger TM, Ronis MJ. Alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis in male mice through activation of the Wnt/β-catenin signaling pathway. Cancer Prev Res (Phila) 2014;7:675-85. [PMID: 24778325 DOI: 10.1158/1940-6207.CAPR-13-0444-T] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
53 Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011;140:1618-1628.e16. [PMID: 21324318 DOI: 10.1053/j.gastro.2011.02.009] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 15.3] [Reference Citation Analysis]
54 Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, Su WW, Chang JG. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008;925-933. [PMID: 18444243 DOI: 10.1002/mc.20446] [Cited by in Crossref: 97] [Cited by in F6Publishing: 80] [Article Influence: 7.5] [Reference Citation Analysis]
55 Chen X, Cheng Q, She M, Wang Q, Huang X, Cao L, Fu X, Chen J. Expression of Sonic Hedgehog Signaling Components in Hepatocellular Carcinoma and Cyclopamine-induced Apoptosis Through Bcl-2 Downregulation In Vitro. Archives of Medical Research 2010;41:315-23. [DOI: 10.1016/j.arcmed.2010.06.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
56 Zakhari S. Chronic alcohol drinking: Liver and pancreatic cancer? Clinics and Research in Hepatology and Gastroenterology 2015;39:S86-91. [DOI: 10.1016/j.clinre.2015.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
57 Dong H, Zhang H, Liang J, Yan H, Chen Y, Shen Y, Kong Y, Wang S, Zhao G, Jin W. Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma. BMC Med Genomics. 2011;4:60. [PMID: 21767414 DOI: 10.1186/1755-8794-4-60] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
58 Choi SS, Omenetti A, Syn WK, Diehl AM. The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol. 2011;43:238-244. [PMID: 21056686 DOI: 10.1016/j.biocel.2010.10.015] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 7.7] [Reference Citation Analysis]
59 Midorikawa Y, Sugiyama Y, Aburatani H. Screening of liver-targeted drugs. Expert Opinion on Drug Discovery 2008;3:643-54. [DOI: 10.1517/17460441.3.6.643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver. 2013;7:696-703. [PMID: 24312711 DOI: 10.5009/gnl.2013.7.6.696] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
61 Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci. 2014;59:365-374. [PMID: 24048683 DOI: 10.1007/s10620-013-2873-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
62 Park HJ, Choi BI, Lee ES, Park SB, Lee JB. How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis. Liver Cancer 2017;6:189-203. [PMID: 28626731 DOI: 10.1159/000455949] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
63 Baghy K, Reszegi A, Tátrai P, Kovalszky I. Decorin in the Tumor Microenvironment. Adv Exp Med Biol 2020;1272:17-38. [PMID: 32845500 DOI: 10.1007/978-3-030-48457-6_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Steins M, Thomas M, Geißler M. Erlotinib. Recent Results Cancer Res 2018;211:1-17. [PMID: 30069756 DOI: 10.1007/978-3-319-91442-8_1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
65 Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
66 Llovet JM. Clinical and molecular classification of hepatocellular carcinoma. Liver Transpl 2007;13:S13-6. [PMID: 17969094 DOI: 10.1002/lt.21325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
67 Varo Pérez E, Castroagudín JF. The future of liver transplantation. Transplant Proc. 2010;42:613-616. [PMID: 20304206 DOI: 10.1016/j.transproceed.2010.02.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
68 Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103:1944-1951. [PMID: 18564111 DOI: 10.1111/j.1572-0241.2008.01922.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
69 Cai X, Li F, Zhang Q, Xu M, Qu Y, Wan X, Gao C, Lu L. Peritumoral ductular reaction is related to nuclear translocation of β-catenin in hepatocellular carcinoma. Biomed Pharmacother 2015;76:11-6. [PMID: 26653544 DOI: 10.1016/j.biopha.2015.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 He AR, Soe K, El Zouhairi M. Current problems with systemic treatment of advanced hepatocellular cancer. Curr Probl Cancer 2010;34:131-49. [PMID: 20417353 DOI: 10.1016/j.currproblcancer.2010.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
71 Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47:1955-1963. [PMID: 18433021 DOI: 10.1002/hep.22256] [Cited by in Crossref: 497] [Cited by in F6Publishing: 452] [Article Influence: 38.2] [Reference Citation Analysis]
72 Weiskirchen R, Mahli A, Weiskirchen S, Hellerbrand C. The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels. Front Physiol 2015;6:140. [PMID: 25999863 DOI: 10.3389/fphys.2015.00140] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
73 Wörns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29. [PMID: 20374038 DOI: 10.1517/13543781003767418] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
74 Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, Galle PR, Factor VM, Park YN, Thorgeirsson SS. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol. 2014;60:346-353. [PMID: 24512821 DOI: 10.1016/j.jhep.2013.10.014] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
75 Lin YT, Liu YC, Chao CC. Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin. Biochem Pharmacol. 2016;122:80-89. [PMID: 27751820 DOI: 10.1016/j.bcp.2016.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
76 Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2012;8:164-171. [PMID: 22524575 DOI: 10.1111/j.1743-7563.2012.01543.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
77 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
78 Liu YJ, Zhou Y, Yeh MM. Recurrent genetic alterations in hepatitis C-associated hepatocellular carcinoma detected by genomic microarray: a genetic, clinical and pathological correlation study. Mol Cytogenet. 2014;7:81. [PMID: 25469175 DOI: 10.1186/s13039-014-0081-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
79 Chua CW, Choo SP. Targeted therapy in hepatocellular carcinoma. Int J Hepatol 2011;2011:348297. [PMID: 21994852 DOI: 10.4061/2011/348297] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
80 Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77. [PMID: 20646772 DOI: 10.1016/j.jhep.2010.05.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
81 Marquardt JU, Andersen JB. Next-generation sequencing: application in liver cancer-past, present and future? Biology (Basel) 2012;1:383-94. [PMID: 23750322 DOI: 10.3390/biology1020383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
82 Tovar V, Villanueva A, Llovet JM. Biología celular y genética en el cáncer de hígado. Gastroenterología y Hepatología 2007;30:360-9. [DOI: 10.1157/13107573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
84 Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010;52:550-9. [PMID: 20206398 DOI: 10.1016/j.jhep.2010.01.015] [Cited by in Crossref: 156] [Cited by in F6Publishing: 143] [Article Influence: 14.2] [Reference Citation Analysis]
85 Ambade A, Satishchandran A, Gyongyosi B, Lowe P, Szabo G. Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease. World J Gastroenterol. 2016;22:4091-4108. [PMID: 27122661 DOI: 10.3748/wjg.v22.i16.4091] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
86 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
87 Saber S, Mahmoud AAA, Goda R, Helal NS, El-Ahwany E, Abdelghany RH. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. Toxicol Lett. 2018;295:32-40. [PMID: 29859236 DOI: 10.1016/j.toxlet.2018.05.036] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
88 Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012;56:267-275. [PMID: 21782758 DOI: 10.1016/j.jhep.2011.07.007] [Cited by in Crossref: 117] [Cited by in F6Publishing: 105] [Article Influence: 11.7] [Reference Citation Analysis]
89 Wang J, Xu X, Liu Z, Wei X, Zhuang R, Lu D, Zhou L, Xie H, Zheng S. LEPREL1 Expression in Human Hepatocellular Carcinoma and Its Suppressor Role on Cell Proliferation. Gastroenterol Res Pract 2013;2013:109759. [PMID: 24319452 DOI: 10.1155/2013/109759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
90 Park YK, Kim KM, Lee YJ, Kim KH, Lee SG, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci 2011;26:214-21. [PMID: 21286012 DOI: 10.3346/jkms.2011.26.2.214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
91 Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-32. [DOI: 10.1038/nrgastro.2009.86] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 6.7] [Reference Citation Analysis]
92 Chen J, Zhou J, Kuang S, Zhang Y, Xie S, He B, Deng Y, Yang H, Shan Q, Wu J, Sirlin CB, Wang J. Liver Imaging Reporting and Data System Category 5: MRI Predictors of Microvascular Invasion and Recurrence After Hepatectomy for Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:821-30. [PMID: 31120791 DOI: 10.2214/AJR.19.21168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
93 Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, Liu C, Qiu YH, Feng FL, Wang JH. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin. 2010;31:1643-1648. [PMID: 21102481 DOI: 10.1038/aps.2010.124] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
94 Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302-S309. [PMID: 20547319 DOI: 10.1016/S1590-8658(10)60521-X] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
95 Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50:590-600. [PMID: 25173447 DOI: 10.1007/s00535-014-0993-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
96 Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;12:1347-57. [DOI: 10.1586/era.12.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
97 Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer 2015;15:542. [PMID: 26206264 DOI: 10.1186/s12885-015-1562-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
98 Xu X, Zou H, Luo L, Wang X, Wang G. MicroRNA-9 exerts antitumor effects on hepatocellular carcinoma progression by targeting HMGA2. FEBS Open Bio 2019;9:1784-97. [PMID: 31408273 DOI: 10.1002/2211-5463.12716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
99 Shang J, Xu S, Zhang J, Ran X, Bai L, Tang H. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017;8:109723-31. [PMID: 29312642 DOI: 10.18632/oncotarget.21299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
100 Verslype C, Rosmorduc O, Rougier P; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii41-vii48. [PMID: 22997453 DOI: 10.1093/annonc/mds225] [Cited by in Crossref: 224] [Cited by in F6Publishing: 206] [Article Influence: 28.0] [Reference Citation Analysis]
101 Yao Y, Bao J, Lu Y, Zhang D, Luo S, Cheng X, Zhang Q, Li S, Liu Q. Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum. Sensors and Actuators B: Chemical 2016;222:127-32. [DOI: 10.1016/j.snb.2015.08.064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
102 Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21:8478-8491. [PMID: 26229392 DOI: 10.3748/wjg.v21.i28.8478] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 81] [Article Influence: 18.8] [Reference Citation Analysis]
103 Chen Q, Yin D, Zhang Y, Yu L, Li XD, Zhou ZJ, Zhou SL, Gao DM, Hu J, Jin C, Wang Z, Shi YH, Cao Y, Fan J, Dai Z, Zhou J. MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis. Cell Death Dis 2017;8:e2906. [PMID: 28661477 DOI: 10.1038/cddis.2017.142] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
104 Carmona-Cuenca I, Roncero C, Sancho P, Caja L, Fausto N, Fernández M, Fabregat I. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol. 2008;49:965-976. [PMID: 18845355 DOI: 10.1016/j.jhep.2008.07.021] [Cited by in Crossref: 155] [Cited by in F6Publishing: 139] [Article Influence: 11.9] [Reference Citation Analysis]
105 Villanueva A, Hoshida Y. Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol. 2011;55:724-725. [PMID: 21616106 DOI: 10.1016/j.jhep.2011.03.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
106 Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol. 2010;15:242-255. [PMID: 20509038 DOI: 10.1007/s10147-010-0089-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
107 Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol. 2017;8:203-213. [PMID: 28638790 DOI: 10.5306/wjco.v8.i3.203] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
108 Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol. 2012;18:6005-6017. [PMID: 23155330 DOI: 10.3748/wjg.v18.i42.6005] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
109 Wang Y, Chen W, Han C, Zhang J, Song K, Kwon H, Dash S, Yao L, Wu T. Adult Hepatocytes Are Hedgehog-Responsive Cells in the Setting of Liver Injury: Evidence for Smoothened-Mediated Activation of NF-κB/Epidermal Growth Factor Receptor/Akt in Hepatocytes that Counteract Fas-Induced Apoptosis. Am J Pathol 2018;188:2605-16. [PMID: 30366594 DOI: 10.1016/j.ajpath.2018.07.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
110 Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 2016;6:21340. [PMID: 26888602 DOI: 10.1038/srep21340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 9.2] [Reference Citation Analysis]
111 Nakayama M, Ogasawara S, Akiba J, Ueda K, Koura K, Todoroki K, Kinoshita H, Yano H. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells. J Gastroenterol Hepatol. 2014;29:1092-1101. [PMID: 24325739 DOI: 10.1111/jgh.12484] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
112 Steins M, Thomas M, Geissler M. Erlotinib. Recent Results Cancer Res 2014;201:109-23. [PMID: 24756788 DOI: 10.1007/978-3-642-54490-3_6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
113 Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77. [PMID: 20962331 DOI: 10.1126/scitranslmed.3001338] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
114 Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis. 2011;29:289-302. [PMID: 21829020 DOI: 10.1159/000327562] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
115 Parent R, Plissonnier M, Bancel B, Liao W, Rumin S, Asaad R, Till M, Sanlaville D, Zoulim F, Trépo C, Marion M. Diversity of Hepatocellular Carcinoma Clones Bearing Hematopoietic Malignancies-Related Chromosomal Translocation: Intrapatient Diversity of HCC Clones. J Cell Biochem 2014;115:666-77. [DOI: 10.1002/jcb.24706] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Caviglia JM, Schwabe RF. Mouse models of liver cancer. Methods Mol Biol 2015;1267:165-83. [PMID: 25636469 DOI: 10.1007/978-1-4939-2297-0_8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
117 Wang Z, Sheng YY, Gao XM, Wang CQ, Wang XY, Lu XU, Wei JW, Zhang KL, Dong QZ, Qin LX. β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol 2015;3:936-40. [PMID: 26171210 DOI: 10.3892/mco.2015.569] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
118 Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43:1021-1029. [PMID: 19747566 DOI: 10.1016/j.biocel.2009.09.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 8.3] [Reference Citation Analysis]
119 Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T, Thorgeirsson SS. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009;69:2775-82. [PMID: 19276364 DOI: 10.1158/0008-5472.CAN-08-3357] [Cited by in Crossref: 115] [Cited by in F6Publishing: 67] [Article Influence: 9.6] [Reference Citation Analysis]
120 Cerrito L, Ponziani FR, Garcovich M, Tortora A, Annicchiarico BE, Pompili M, Siciliano M, Gasbarrini A. Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19:1941-1948. [PMID: 30345837 DOI: 10.1080/14656566.2018.1534956] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
121 Liu M, Jiang K, Lin G, Liu P, Yan Y, Ye T, Yao G, Barr MP, Liang D, Wang Y, Gong P, Meng S, Piao H. Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation. J Exp Clin Cancer Res 2018;37:165. [PMID: 30041665 DOI: 10.1186/s13046-018-0806-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
122 Sieghart W, Wang X, Schmid K, Pinter M, König F, Bodingbauer M, Wrba F, Rasoul-Rockenschaub S, Peck-Radosavljevic M. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol. 2011;54:89-97. [PMID: 20970216 DOI: 10.1016/j.jhep.2010.06.030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
123 Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-410. [PMID: 23469975 DOI: 10.2217/fon.13.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
124 Wee A. Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations. Patholog Res Int 2011;2011:587936. [PMID: 21789263 DOI: 10.4061/2011/587936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
125 Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. Clin Liver Dis 2011;15:307-21, vii-x. [PMID: 21689615 DOI: 10.1016/j.cld.2011.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
126 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 535] [Article Influence: 44.3] [Reference Citation Analysis]
127 Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1:83-93. [PMID: 24159576 DOI: 10.1159/0003424-05] [Reference Citation Analysis]
128 Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, Di Marco V, Farinati F, Del Poggio P, Borzio F. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis. 2011;43:875-880. [PMID: 21684821 DOI: 10.1016/j.dld.2011.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
129 Hannivoort RA, Hernandez-Gea V, Friedman SL. Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair 2012;5:1. [PMID: 22214245 DOI: 10.1186/1755-1536-5-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
130 Wu J, Zhang W, Xu A, Zhang L, Yan T, Li Z, Wu X, Zhu X, Ma J, Li K. Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China. Genet Test Mol Biomarkers. 2013;17:595-600. [PMID: 23790025 DOI: 10.1089/gtmb.2013.0031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
131 Zhou B, Chen H, Wei D, Kuang Y, Zhao X, Li G, Xie J, Chen P. A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res 2014;33:55. [PMID: 24980149 DOI: 10.1186/1756-9966-33-55] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
132 Steins M, Thomas M, Geißler M. Erlotinib. In: Martens UM, editor. Small Molecules in Oncology. Berlin: Springer Berlin Heidelberg; 2010. pp. 21-31. [DOI: 10.1007/978-3-642-01222-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
133 Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: a tale of “second hit”. World J Gastroenterol. 2013;19:1158-1165. [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 87] [Article Influence: 12.3] [Reference Citation Analysis]
134 Santhekadur PK, Akiel M, Emdad L, Gredler R, Srivastava J, Rajasekaran D, Robertson CL, Mukhopadhyay ND, Fisher PB, Sarkar D. Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling. FEBS Open Bio 2014;4:353-61. [PMID: 24918049 DOI: 10.1016/j.fob.2014.03.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
135 Feng X, Ma G, Shi H, Wang Y, Chao X. An Integrative Serum Pharmacology-Based Approach to Study the Anti-Tumor Activity of B. paniculatum Aqueous Bulb Extract on the Human Hepatocellular Carcinoma Cell Line BEL-7404. Front Pharmacol 2020;11:01261. [PMID: 33123002 DOI: 10.3389/fphar.2020.01261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Chang C, Huang T, Lin K, Hsu C, Chang W, Wang S, Ko F, Peng H, Chung C. 4-Acetylantroquinonol B Suppresses Tumor Growth and Metastasis of Hepatoma Cells via Blockade of Translation-Dependent Signaling Pathway and VEGF Production. J Agric Food Chem 2015;63:208-15. [DOI: 10.1021/jf504434v] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
137 Kaneko S, Ikeda K, Matsuzaki Y, Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol 2016;51:1011-21. [PMID: 26931117 DOI: 10.1007/s00535-016-1173-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
138 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
139 Shan YF, Huang YL, Xie YK, Tan YH, Chen BC, Zhou MT, Shi HQ, Yu ZP, Song QT, Zhang QY. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status. Med Oncol. 2011;28:1012-1016. [PMID: 20571936 DOI: 10.1007/s12032-010-9600-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
140 Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 2012;5:ra24. [PMID: 22457330 DOI: 10.1126/scisignal.2002739] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 12.6] [Reference Citation Analysis]
141 Zhao J, Adams A, Roberts B, O'Neil M, Vittal A, Schmitt T, Kumer S, Cox J, Li Z, Weinman SA, Tikhanovich I. Protein arginine methyl transferase 1- and Jumonji C domain-containing protein 6-dependent arginine methylation regulate hepatocyte nuclear factor 4 alpha expression and hepatocyte proliferation in mice. Hepatology 2018;67:1109-26. [PMID: 29023917 DOI: 10.1002/hep.29587] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
142 Giakoustidis A, Giakoustidis D, Mudan S, Sklavos A, Williams R. Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1. Can J Gastroenterol Hepatol 2015;29:209-17. [PMID: 25965442 DOI: 10.1155/2015/172356] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
143 Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer. 2010;116:1315-1325. [PMID: 20101735 DOI: 10.1002/cncr.24863] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
144 Rajasekaran D, Srivastava J, Ebeid K, Gredler R, Akiel M, Jariwala N, Robertson CL, Shen XN, Siddiq A, Fisher PB, Salem AK, Sarkar D. Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC). Bioconjug Chem 2015;26:1651-61. [PMID: 26079152 DOI: 10.1021/acs.bioconjchem.5b00254] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
145 Mao J, Wang D, Wang Z, Tian W, Li X, Duan J, Wang Y, Yang H, You L, Cheng Y, Bian J, Chen Z, Yang Y. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway. Cancer Lett 2016;380:134-43. [PMID: 27349166 DOI: 10.1016/j.canlet.2016.06.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
146 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 289] [Article Influence: 31.0] [Reference Citation Analysis]
147 Su H, Zhao J, Xiong Y, Xu T, Zhou F, Yuan Y, Zhang Y, Zhuang SM. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res. 2008;641:27-35. [PMID: 18358501 DOI: 10.1016/j.mrfmmm.2008.02.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
148 Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol. 2017;27:4472-4481. [PMID: 28439654 DOI: 10.1007/s00330-017-4844-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
149 Chen Q, Tan L, Jin Z, Liu Y, Zhang Z. Downregulation of CRABP2 Inhibit the Tumorigenesis of Hepatocellular Carcinoma In Vivo and In Vitro. Biomed Res Int 2020;2020:3098327. [PMID: 32685464 DOI: 10.1155/2020/3098327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Vucur M, Roderburg C, Bettermann K, Tacke F, Heikenwalder M, Trautwein C, Luedde T. Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma? Oncotarget 2010;1:373-8. [PMID: 21307402 DOI: 10.18632/oncotarget.100906] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
151 Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20. [PMID: 20953207 DOI: 10.1038/aps.2010.142] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 9.4] [Reference Citation Analysis]
152 Cornellà H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res. 2011;35:821-825. [PMID: 21303380 DOI: 10.1111/j.1530-0277.2010.01406.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
153 Liu Z, Li J, Li J, Huang J, Ke F, Qi Q, Jiang X, Zhong Z. Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice. Int J Nanomedicine 2012;7:5039-49. [PMID: 23055722 DOI: 10.2147/IJN.S34022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
154 Zhao J, O'Neil M, Vittal A, Weinman SA, Tikhanovich I. PRMT1-Dependent Macrophage IL-6 Production Is Required for Alcohol-Induced HCC Progression. Gene Expr 2019;19:137-50. [PMID: 30236171 DOI: 10.3727/105221618X15372014086197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
155 Lu H, Chou F, Yeh K, Chang Y, Hsu NC, Chang J. Expression of Protein Kinase C Family in Human Hepatocellular Carcinoma. Pathol Oncol Res 2010;16:385-91. [DOI: 10.1007/s12253-009-9228-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
156 Lyra-gonzález I, Flores-fong LE, González-garcía I, Medina-preciado D, Armendáriz-borunda J. Adenoviral gene therapy in hepatocellular carcinoma: a review. Hepatol Int 2013;7:48-58. [DOI: 10.1007/s12072-012-9367-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
157 Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis. 2013;45:510-515. [PMID: 23218990 DOI: 10.1016/j.dld.2012.10.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
158 Xin Z, Zhang W, Xu A, Zhang L, Yan T, Li Z, Wu X, Zhu X, Ma J, Li K. Polymorphisms in the potential functional regions of the TGF-β 1 and TGF-β receptor genes and disease susceptibility in HBV-related hepatocellular carcinoma patients. Mol Carcinog. 2012;51 Suppl 1:E123-E131. [PMID: 22290546 DOI: 10.1002/mc.21876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
159 West CA, Black AP, Mehta AS. Analysis of Hepatocellular Carcinoma Tissue for Biomarker Discovery. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 93-107. [DOI: 10.1007/978-3-030-21540-8_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
160 Marquardt JU, Thorgeirsson SS. Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis. 2010;30:26-34. [PMID: 20175031 DOI: 10.1055/s-0030-1247130] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
161 Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43:1021-1029. [PMID: 19747566 DOI: 10.1016/j.biocel.2009.09.001s1357-2725(09)00244-1] [Reference Citation Analysis]
162 Li C, Zhang F, Zhang W, Zhang L, Huang Z, Wu P. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:1633-1640. [PMID: 20865361 DOI: 10.1007/s00432-010-0821-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
163 Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013;7:87-102. [PMID: 23761989 DOI: 10.4137/CMO.S7633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
164 Kim J, Hong SJ, Park JY, Park JH, Yu Y, Park SY, Lim EK, Choi KY, Lee EK, Paik SS, Lee KG, Wang HJ, Do I, Joh J, Kim DS; on behalf of the Korea Cancer Biomarker Consortium. Epithelial-mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. Cancer Science 2010;101:1521-8. [DOI: 10.1111/j.1349-7006.2010.01536.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
165 Kim E, Kim D, Lee JS, Yoe J, Park J, Kim CJ, Jeong D, Kim S, Lee Y. Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis. Hepatology 2018;67:2287-301. [PMID: 29251790 DOI: 10.1002/hep.29738] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
166 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology. 2008;47:2059-2067. [PMID: 18506891 DOI: 10.1002/hep.22283] [Cited by in Crossref: 227] [Cited by in F6Publishing: 213] [Article Influence: 17.5] [Reference Citation Analysis]
167 Chang MH. Prevention of Hepatitis B Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:71-90. [PMID: 33200362 DOI: 10.1007/978-3-030-57362-1_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-82. [PMID: 18650841 DOI: 10.1038/nrc2399] [Cited by in Crossref: 553] [Cited by in F6Publishing: 484] [Article Influence: 46.1] [Reference Citation Analysis]
169 Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer. 2010;10:354. [PMID: 20602797 DOI: 10.1186/1471-2407-10-354] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 9.9] [Reference Citation Analysis]
170 Gui Y, Yeganeh M, Ramanathan S, Leblanc C, Pomerleau V, Ferbeyre G, Saucier C, Ilangumaran S. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J Hepatol 2011;55:1300-8. [PMID: 21703184 DOI: 10.1016/j.jhep.2011.03.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
171 Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, Goria O, Hiron M, Daveau M, Salier JP. Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol 2009;15:300-9. [PMID: 19140229 DOI: 10.3748/wjg.15.300] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
172 Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, Lu X, Zhang Y, Lin X, Xu G. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 2012;403:203-13. [PMID: 22349331 DOI: 10.1007/s00216-012-5782-4] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 10.9] [Reference Citation Analysis]
173 Paradis V. Histopathology of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:21-32. [PMID: 22941011 DOI: 10.1007/978-3-642-16037-0_2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
174 Lièvre A, Landi B, Mitry E, Taïeb J. Les antiangiogéniques en oncologie digestive. Gastroentérologie Clinique et Biologique 2008;32:504-20. [DOI: 10.1016/j.gcb.2008.01.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
175 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1557] [Article Influence: 321.3] [Reference Citation Analysis]
176 Kashofer K, Tschernatsch MM, Mischinger HJ, Iberer F, Zatloukal K. The disease relevance of human hepatocellular xenograft models: molecular characterization and review of the literature. Cancer Lett 2009;286:121-8. [PMID: 19111389 DOI: 10.1016/j.canlet.2008.11.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
177 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 236] [Article Influence: 43.3] [Reference Citation Analysis]
178 Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C. Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int. 2014;2014:806391. [PMID: 24900987 DOI: 10.1155/2014/806391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
179 Paradis V. Hepatocellular Carcinomas: Towards a pathomolecular approach. Liver Int 2021;41 Suppl 1:83-8. [PMID: 34155797 DOI: 10.1111/liv.14867] [Reference Citation Analysis]
180 Wei W, Wu S, Wang X, Sun CK, Yang X, Yan X, Chua MS, So S. Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget 2014;5:5819-31. [PMID: 25051375 DOI: 10.18632/oncotarget.2171] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
181 Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9:1533-1548. [PMID: 24106903 DOI: 10.2217/fon.13.171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
182 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014;20:16630-8. [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
183 Murakami Y, Tamori A, Itami S, Tanahashi T, Toyoda H, Tanaka M, Wu W, Brojigin N, Kaneoka Y, Maeda A. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer. 2013;13:99. [PMID: 23496901 DOI: 10.1186/1471-2407-13-99] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
184 Wörns MA, Galle PR. HCC therapies--lessons learned. Nat Rev Gastroenterol Hepatol 2014;11:447-52. [PMID: 24492278 DOI: 10.1038/nrgastro.2014.10] [Cited by in Crossref: 98] [Cited by in F6Publishing: 86] [Article Influence: 14.0] [Reference Citation Analysis]
185 Ye F, Che Y, McMillen E, Gorski J, Brodman D, Saw D, Jiang B, Zhang DY. The effect of Scutellaria baicalensis on the signaling network in hepatocellular carcinoma cells. Nutr Cancer. 2009;61:530-537. [PMID: 19838925 DOI: 10.1080/01635580902803719] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
186 Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80:550-560. [PMID: 20371362 DOI: 10.1016/j.bcp.2010.03.034] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.7] [Reference Citation Analysis]
187 Liu YC, Yeh CT, Lin KH. Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies. Cells 2020;9:E1331. [PMID: 32466488 DOI: 10.3390/cells9061331] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 19.0] [Reference Citation Analysis]
188 Aicher S, Kakkanas A, Cohen L, Blumen B, Oprisan G, Njouom R, Meurs EF, Mavromara P, Martin A. Differential regulation of the Wnt/β-catenin pathway by hepatitis C virus recombinants expressing core from various genotypes. Sci Rep 2018;8:11185. [PMID: 30046100 DOI: 10.1038/s41598-018-29078-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
189 Rodríguez-Hernández MA, Chapresto-Garzón R, Cadenas M, Navarro-Villarán E, Negrete M, Gómez-Bravo MA, Victor VM, Padillo FJ, Muntané J. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell Death Dis 2020;11:339. [PMID: 32382022 DOI: 10.1038/s41419-020-2558-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
190 Brar TS, Hilgenfeldt E, Soldevila-pico C. Etiology and Pathogenesis of Hepatocellular Carcinoma. In: Liu C, editor. Precision Molecular Pathology of Liver Cancer. Cham: Springer International Publishing; 2018. pp. 1-15. [DOI: 10.1007/978-3-319-68082-8_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
191 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
192 Liu YX, Li QZ, Cao YN, Zhang LQ. Identification of key genes and important histone modifications in hepatocellular carcinoma. Comput Struct Biotechnol J 2020;18:2657-69. [PMID: 33033585 DOI: 10.1016/j.csbj.2020.09.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
193 Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;5. [PMID: 27239288 DOI: 10.12688/f1000research.6946.1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 14.0] [Reference Citation Analysis]
194 Chang MH. Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res 2014;193:75-95. [PMID: 24008294 DOI: 10.1007/978-3-642-38965-8_5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
195 Su PF, Lee TC, Lin PJ, Lee PH, Jeng YM, Chen CH, Liang JD, Chiou LL, Huang GT, Lee HS. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer. 2007;121:1257-1264. [PMID: 17534893 DOI: 10.1002/ijc.22849] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
196 Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol. 2010;2:348-359. [PMID: 21160806 DOI: 10.4251/wjgo.v2.i9.348] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
197 Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res 2021;149:63-101. [PMID: 33579428 DOI: 10.1016/bs.acr.2020.10.002] [Reference Citation Analysis]
198 Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9:739-745. [PMID: 19496710 DOI: 10.1586/era.09.41] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
199 Xie J. Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai) 2008;40:670-80. [PMID: 18604459 DOI: 10.1111/j.1745-7270.2008.00431.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
200 Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526-3536. [PMID: 19617899 DOI: 10.1038/onc.2009.211] [Cited by in Crossref: 484] [Cited by in F6Publishing: 447] [Article Influence: 40.3] [Reference Citation Analysis]
201 Xiao S, Liu Z, Deng R, Li C, Fu S, Chen G, Zhang X, Ke F, Ke S, Yu X, Wang S, Zhong Z. Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo. J Control Release. 2017;258:130-145. [PMID: 28522194 DOI: 10.1016/j.jconrel.2017.05.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
202 Kirovski G, Stevens AP, Czech B, Dettmer K, Weiss TS, Wild P, Hartmann A, Bosserhoff AK, Oefner PJ, Hellerbrand C. Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA). Am J Pathol 2011;178:1145-52. [PMID: 21356366 DOI: 10.1016/j.ajpath.2010.11.059] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
203 Frau M, Tomasi ML, Simile MM, Demartis MI, Salis F, Latte G, Calvisi DF, Seddaiu MA, Daino L, Feo CF, Brozzetti S, Solinas G, Yamashita S, Ushijima T, Feo F, Pascale RM. Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology. 2012;56:165-175. [PMID: 22318685 DOI: 10.1002/hep.25643] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
204 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 145] [Article Influence: 14.5] [Reference Citation Analysis]
205 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3196] [Article Influence: 404.7] [Reference Citation Analysis]
206 Lee JM, Yang J, Newell P, Singh S, Parwani A, Friedman SL, Nejak-Bowen KN, Monga SP. β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett 2014;343:90-7. [PMID: 24071572 DOI: 10.1016/j.canlet.2013.09.020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
207 Pascale RM, Joseph C, Latte G, Evert M, Feo F, Calvisi DF. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma? DNA Repair 2016;47:12-20. [DOI: 10.1016/j.dnarep.2016.10.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
208 Guo Y, Peng Y, Gao D, Zhang M, Yang W, Linghu E, Herman JG, Fuks F, Dong G, Guo M. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma. Clin Epigenetics 2017;9:116. [PMID: 29075359 DOI: 10.1186/s13148-017-0412-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
209 Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. J Biol Chem. 2013;288:18249-18259. [PMID: 23677989 DOI: 10.1074/jbc.m112.446385] [Cited by in Crossref: 65] [Cited by in F6Publishing: 31] [Article Influence: 8.1] [Reference Citation Analysis]
210 El-Kawy OA, Talaat HM. Preparation, characterization and evaluation of (186) Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma. J Labelled Comp Radiopharm 2016;59:72-7. [PMID: 26725469 DOI: 10.1002/jlcr.3368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
211 Pivonello C, Negri M, De Martino MC, Napolitano M, de Angelis C, Provvisiero DP, Cuomo G, Auriemma RS, Simeoli C, Izzo F, Colao A, Hofland LJ, Pivonello R. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget 2016;7:9718-31. [PMID: 26756219 DOI: 10.18632/oncotarget.6836] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
212 Farris AB, Dursun N, Dhanasekaran R, Coban I, McIntosh EB, Adsay NV, Kim HS. Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. Pathol Res Pract. 2012;208:15-21. [PMID: 22088254 DOI: 10.1016/j.prp.2011.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
213 Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011;208:1963-1976. [PMID: 21875955 DOI: 10.1084/jem.20110198] [Cited by in Crossref: 137] [Cited by in F6Publishing: 116] [Article Influence: 13.7] [Reference Citation Analysis]
214 Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol. 2010;52:79-87. [PMID: 19910069 DOI: 10.1016/j.jhep.2009.10.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
215 Wang Y, Chen CL, Pan QZ, Wu YY, Zhao JJ, Jiang SS, Chao J, Zhang XF, Zhang HX, Zhou ZQ, Tang Y, Huang XQ, Zhang JH, Xia JC. Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget 2016;7:6323-34. [PMID: 26575170 DOI: 10.18632/oncotarget.6319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
216 Copeland NG, Jenkins NA. Harnessing transposons for cancer gene discovery. Nat Rev Cancer 2010;10:696-706. [PMID: 20844553 DOI: 10.1038/nrc2916] [Cited by in Crossref: 124] [Cited by in F6Publishing: 97] [Article Influence: 11.3] [Reference Citation Analysis]
217 Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385-7392. [PMID: 19723656 DOI: 10.1158/0008-5472.can-09-1089] [Cited by in Crossref: 619] [Cited by in F6Publishing: 369] [Article Influence: 51.6] [Reference Citation Analysis]
218 Hao PP, Liu YP, Yang CY, Liang T, Zhang C, Song J, Han JK, Hou GH. Evaluation of (131)I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma. PLoS One 2014;9:e85002. [PMID: 24416333 DOI: 10.1371/journal.pone.0085002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
219 de Oliveira RM, Ornelas Ricart CA, Araujo Martins AM. Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma. Front Oncol. 2017;7:328. [PMID: 29379771 DOI: 10.3389/fonc.2017.00328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
220 Che Y, Ye F, Xu R, Qing H, Wang X, Yin F, Cui M, Burstein D, Jiang B, Zhang DY. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol 2012;180:1798-807. [PMID: 22429965 DOI: 10.1016/j.ajpath.2012.01.016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
221 Chen CP, Haas-kogan D. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics 2014;10:883-95. [DOI: 10.1586/erm.10.76] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
222 Jung N, Won JK, Kim BH, Suh KS, Jang JJ, Kang GH. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma. J Korean Med Sci 2012;27:594-604. [PMID: 22690089 DOI: 10.3346/jkms.2012.27.6.594] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
223 Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, Luo Y, Jian Z, Zhou X. lncAKHE enhances cell growth and migration in hepatocellular carcinoma via activation of NOTCH2 signaling. Cell Death Dis 2018;9:487. [PMID: 29706630 DOI: 10.1038/s41419-018-0554-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
224 Zhu Y, Tang H, Zhang L, Gong L, Wu G, Ni J, Tang X. Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN. Cancer Manag Res 2019;11:955-68. [PMID: 30774424 DOI: 10.2147/CMAR.S183328] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
225 Tveteraas IH, Müller KM, Aasrum M, Ødegård J, Dajani O, Guren T, Sandnes D, Christoffersen T. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. J Exp Clin Cancer Res 2012;31:72. [PMID: 22967907 DOI: 10.1186/1756-9966-31-72] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
226 Gao C. Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma. World J Hepatol 2016;8:1119-27. [PMID: 27721917 DOI: 10.4254/wjh.v8.i27.1119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
227 Lin YT, Lu HP, Chao CC. Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis. Biochem Pharmacol 2015;93:110-24. [PMID: 25451688 DOI: 10.1016/j.bcp.2014.10.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
228 Kim JY, Lee HY, Park KK, Choi YK, Nam JS, Hong IS. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget. 2016;7:20395-20409. [PMID: 26967248 DOI: 10.18632/oncotarget.7954] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
229 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
230 He Y, Liu X. The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K/Akt pathway. Biomedicine & Pharmacotherapy 2015;76:141-6. [DOI: 10.1016/j.biopha.2015.10.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
231 Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E. Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel) 2018;10:E481. [PMID: 30513925 DOI: 10.3390/cancers10120481] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 22.7] [Reference Citation Analysis]
232 Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009;29 Suppl 1:148-58. [PMID: 19207980 DOI: 10.1111/j.1478-3231.2008.01929.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
233 Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Solé M, Lee WL, Kuka TP, Moriarity BS. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology. 2013;57:120-130. [PMID: 22899566 DOI: 10.1002/hep.26004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
234 Khattab M, Fouad M, Ahmed E. Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World J Hepatol 2015;7:2474-81. [PMID: 26483869 DOI: 10.4254/wjh.v7.i23.2474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
235 Khan MA, Raza A, Ovais M, Sohail MF, Ali S. Current state and prospects of nano-delivery systems for sorafenib. International Journal of Polymeric Materials and Polymeric Biomaterials 2018;67:1105-15. [DOI: 10.1080/00914037.2018.1429434] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
236 Tsiambas E, Manaios L, Papanikolopoulos C, Rigopoulos DN, Tsounis D, Karameris A, Soultati A, Koliopoulou A, Kravvaritis C, Sergentanis T. Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays. Pathol Oncol Res. 2009;15:511-520. [PMID: 19145479 DOI: 10.1007/s12253-008-9146-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
237 Guimei M, Baddour N, Elkaffash D, Abdou L, Taher Y. Gremlin in the pathogenesis of hepatocellular carcinoma complicating chronic hepatitis C: an immunohistochemical and PCR study of human liver biopsies. BMC Res Notes 2012;5:390. [PMID: 22839096 DOI: 10.1186/1756-0500-5-390] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
238 Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clin Transl Oncol. 2013;15:146-153. [PMID: 22875650 DOI: 10.1007/s12094-012-0902-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
239 Horváth Z, Kovalszky I, Fullár A, Kiss K, Schaff Z, Iozzo RV, Baghy K. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol 2014;35:194-205. [PMID: 24361483 DOI: 10.1016/j.matbio.2013.11.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
240 Braconi C, Valeri N, Kogure T, Gasparini P, Huang N, Nuovo GJ, Terracciano L, Croce CM, Patel T. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2011;108:786-791. [PMID: 21187392 DOI: 10.1073/pnas.1011098108] [Cited by in Crossref: 149] [Cited by in F6Publishing: 140] [Article Influence: 13.5] [Reference Citation Analysis]
241 Wysocki PJ. Targeted therapy of hepatocellular cancer. Expert Opinion on Investigational Drugs 2010;19:265-74. [DOI: 10.1517/13543780903514110] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
242 Bohinc BN, Diehl AM. Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis. 2012;16:549-565. [PMID: 22824480 DOI: 10.1016/j.cld.2012.05.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
243 Takai A, Dang HT, Wang XW. Identification of drivers from cancer genome diversity in hepatocellular carcinoma. Int J Mol Sci. 2014;15:11142-11160. [PMID: 24955791 DOI: 10.3390/ijms150611142] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
244 Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for hepatocellular carcinoma? J Hepatol. 2012;57:453-454. [PMID: 22425699 DOI: 10.1016/j.jhep.2012.03.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
245 Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 2012;1:83-93. [PMID: 24159576 DOI: 10.1159/000342405] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 15.9] [Reference Citation Analysis]
246 Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med. 2007;11:981-1011. [PMID: 17979879 DOI: 10.1111/j.1582-4934.2007.00088.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 11.2] [Reference Citation Analysis]
247 Ezzat WM, Amr KS. Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention. World J Hepatol 2016;8:1251-61. [PMID: 27843535 DOI: 10.4254/wjh.v8.i30.1251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
248 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
249 Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015;6:3211-3224. [PMID: 25633810 DOI: 10.18632/oncotarget.3085] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 20.2] [Reference Citation Analysis]
250 Castven D, Becker D, Czauderna C, Wilhelm D, Andersen JB, Strand S, Hartmann M, Heilmann‐heimbach S, Roth W, Hartmann N, Straub BK, Mahn FL, Franck S, Pereira S, Haupts A, Vogel A, Wörns MA, Weinmann A, Heinrich S, Lang H, Thorgeirsson SS, Galle PR, Marquardt JU. Application of patient‐derived liver cancer cells for phenotypic characterization and therapeutic target identification. Int J Cancer 2019;144:2782-94. [DOI: 10.1002/ijc.32026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
251 Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20:9217-9228. [PMID: 25071314 DOI: 10.3748/wjg.v20.i28.9217] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
252 Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int 2021;21:208. [PMID: 33849569 DOI: 10.1186/s12935-021-01924-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opinion on Emerging Drugs 2010;15:13-26. [DOI: 10.1517/14728210903571659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
254 Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G. Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett. 2015;9:1201-1206. [PMID: 25663882 DOI: 10.3892/ol.2014.2823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
255 Petrillo M, Patella F, Pesapane F, Suter MB, Ierardi AM, Angileri SA, Floridi C, de Filippo M, Carrafiello G. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncology 2018;14:2957-67. [DOI: 10.2217/fon-2017-0739] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
256 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
257 Tu J, Chen Y, Cai L, Xu C, Zhang Y, Chen Y, Zhang C, Zhao J, Cheng J, Xie H. Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation. J Proteome Res. 2015;14:2385-2397. [PMID: 25869096 DOI: 10.1021/acs.jproteome.5b00062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
258 Srivastava S, Thakkar B, Yeoh KG, Ho KY, Teh M, Soong R, Salto-tellez M. Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma. Virchows Arch 2015;466:541-8. [DOI: 10.1007/s00428-015-1745-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
259 Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31:461-76. [PMID: 19925500 DOI: 10.1111/j.1365-2036.2009.04200.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 120] [Article Influence: 10.8] [Reference Citation Analysis]
260 Chiang KC, Yeh CN, Chen HY, Lee JM, Juang HH, Chen MF, Takano M, Kittaka A, Chen TC. 19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids. 2011;76:1513-1519. [PMID: 21888924 DOI: 10.1016/j.steroids.2011.08.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
261 Ma Y, Cao, Li G, Hu J, Liu X, Liu J. Silence of lncRNA HEIH suppressed liver cancer cell growth and metastasis through miR-199a-3p/mTOR axis. J Cell Biochem 2019;120:17757-66. [PMID: 31144384 DOI: 10.1002/jcb.29041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
262 Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 2010;31:179-93. [PMID: 20176048 DOI: 10.1016/j.mam.2010.02.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
263 Liu YX, Zhang SF, Ji YH, Guo SJ, Wang GF, Zhang GW. Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient. Oncol Lett 2012;4:847-51. [PMID: 23205112 DOI: 10.3892/ol.2012.825] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
264 Abdel Aziz MT, Khaled HM, El Hindawi A, Roshdy NK, Rashed LA, Sabry D, Hassouna AA, Taha F, Ali WI. Effect of mesenchymal stem cells and a novel curcumin derivative on Notch1 signaling in hepatoma cell line. Biomed Res Int 2013;2013:129629. [PMID: 24024180 DOI: 10.1155/2013/129629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
265 Wang X, Huo B, Liu J, Huang X, Zhang S, Feng T. Hepatitis B virus X reduces hepatocyte apoptosis and promotes cell cycle progression through the Akt/mTOR pathway in vivo. Gene 2019;691:87-95. [PMID: 30630095 DOI: 10.1016/j.gene.2018.12.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
266 Frau M, Simile MM, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, Feo CF, Massarelli G, Solinas G, Feo F, Lee JS, Pascale RM. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr) 2012;35:163-73. [PMID: 22434528 DOI: 10.1007/s13402-011-0067-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
267 Khan MGM, Ghosh A, Variya B, Santharam MA, Kandhi R, Ramanathan S, Ilangumaran S. Hepatocyte growth control by SOCS1 and SOCS3. Cytokine. 2019;121:154733. [PMID: 31154249 DOI: 10.1016/j.cyto.2019.154733] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
268 Rajasekaran D, Jariwala N, Mendoza RG, Robertson CL, Akiel MA, Dozmorov M, Fisher PB, Sarkar D. Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL). J Biol Chem 2016;291:10736-46. [PMID: 26997225 DOI: 10.1074/jbc.M116.715359] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
269 Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989-5005. [PMID: 20639898 DOI: 10.1038/onc.2010.236] [Cited by in Crossref: 562] [Cited by in F6Publishing: 509] [Article Influence: 51.1] [Reference Citation Analysis]
270 Aleksic K, Lackner C, Geigl JB, Schwarz M, Auer M, Ulz P, Fischer M, Trajanoski Z, Otte M, Speicher MR. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice. Hepatology 2011;53:895-904. [PMID: 21374661 DOI: 10.1002/hep.24133] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
271 Dawson SP. Hepatocellular carcinoma and the ubiquitin-proteasome system. Biochim Biophys Acta 2008;1782:775-84. [PMID: 18778769 DOI: 10.1016/j.bbadis.2008.08.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
272 Efroni S, Meerzaman D, Schaefer CF, Greenblum S, Soo-Lyu M, Hu Y, Cultraro C, Meshorer E, Buetow KH. Systems analysis utilising pathway interactions identifies sonic hedgehog pathway as a primary biomarker and oncogenic target in hepatocellular carcinoma. IET Syst Biol 2013;7:243-51. [PMID: 24712101 DOI: 10.1049/iet-syb.2010.0078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
273 Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets. 2008;9:1013-1024. [PMID: 18991612 DOI: 10.2174/138945008786786127] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 8.6] [Reference Citation Analysis]
274 Newell P, Villanueva A, Llovet JM. Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. Journal of Hepatology 2008;49:1-5. [DOI: 10.1016/j.jhep.2008.04.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
275 Tanaka Y, Kanai F, Tada M, Tateishi R, Sanada M, Nannya Y, Ohta M, Asaoka Y, Seto M, Shiina S, Yoshida H, Kawabe T, Yokosuka O, Ogawa S, Omata M. Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. J Hepatol. 2008;49:746-757. [PMID: 18752864 DOI: 10.1016/j.jhep.2008.06.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
276 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
277 Zhang N, Chu ES, Zhang J, Li X, Liang Q, Chen J, Chen M, Teoh N, Farrell G, Sung JJ, Yu J. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway. Oncotarget 2014;5:8330-40. [PMID: 25327562 DOI: 10.18632/oncotarget.2212] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
278 Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 2008;25:1089-1104. [PMID: 18972075 DOI: 10.1007/s12325-008-0113-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
279 de Boussac H, Orbán TI, Várady G, Tihanyi B, Bacquet C, Brózik A, Váradi A, Sarkadi B, Arányi T. Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters. Biochemical and Biophysical Research Communications 2012;426:172-6. [DOI: 10.1016/j.bbrc.2012.08.046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
280 Buonaguro L; HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother 2016;65:93-9. [PMID: 26093657 DOI: 10.1007/s00262-015-1728-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
281 Hytiroglou P, Park YN, Krinsky G, Theise ND. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am. 2007;36:867-87, vii. [PMID: 17996795 DOI: 10.1016/j.gtc.2007.08.010] [Cited by in Crossref: 98] [Cited by in F6Publishing: 65] [Article Influence: 7.5] [Reference Citation Analysis]
282 Sia D, Villanueva A. Signaling pathways in hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:18-23. [PMID: 22212931 DOI: 10.1159/000333254] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
283 Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725-733. [PMID: 19665249 DOI: 10.1016/j.jhep.2009.03.028] [Cited by in Crossref: 160] [Cited by in F6Publishing: 133] [Article Influence: 13.3] [Reference Citation Analysis]
284 Ai L, Xu Z, Yang B, He Q, Luo P. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol 2019;12:1121-7. [PMID: 31679411 DOI: 10.1080/17512433.2019.1689122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
285 Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-1983, 1983.e1-1983.11. [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008] [Cited by in Crossref: 482] [Cited by in F6Publishing: 454] [Article Influence: 37.1] [Reference Citation Analysis]
286 Cha J, Seong J, Lee IJ, Kim JW, Han KH. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J. 2013;54:1178-1185. [PMID: 23918567 DOI: 10.3349/ymj.2013.54.5.1178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
287 Zhang R, Sun J, Zhang Y, Cheng S, Zhang X. Signal transduction disturbance related to hepatocarcinogenesis in mouse by prolonged exposure to Nanjing drinking water. Environ Sci Pollut Res 2013;20:6468-81. [DOI: 10.1007/s11356-013-1695-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
288 Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol 2012;4:256-61. [PMID: 23060970 DOI: 10.4254/wjh.v4.i9.256] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
289 Zhao J, O'Neil M, Schonfeld M, Komatz A, Weinman SA, Tikhanovich I. Hepatocellular Protein Arginine Methyltransferase 1 Suppresses Alcohol-Induced Hepatocellular Carcinoma Formation by Inhibition of Inducible Nitric Oxide Synthase. Hepatol Commun 2020;4:790-808. [PMID: 32490317 DOI: 10.1002/hep4.1488] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
290 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med. 2016;6:21-36. [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 60] [Article Influence: 14.6] [Reference Citation Analysis]
291 Mansuroglu T, Baumhoer D, Dudas J, Haller F, Cameron S, Lorf T, Füzesi L, Ramadori G. Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells: . European Journal of Gastroenterology & Hepatology 2009;21:1206-11. [DOI: 10.1097/meg.0b013e328317f4ef] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
292 Robertson CL, Srivastava J, Siddiq A, Gredler R, Emdad L, Rajasekaran D, Akiel M, Shen XN, Guo C, Giashuddin S. Genetic deletion of AEG-1 prevents hepatocarcinogenesis. Cancer Res. 2014;74:6184-6193. [PMID: 25193383 DOI: 10.1158/0008-5472.CAN-14-1357] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
293 Chiang KC, Yeh CN, Chen MF, Chen TC. Hepatocellular carcinoma and vitamin D: a review. J Gastroenterol Hepatol. 2011;26:1597-1603. [PMID: 21880026 DOI: 10.1111/j.1440-1746.2011.06892.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
294 van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H, Mikulits W. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 2009;5:1169-79. [PMID: 19852728 DOI: 10.2217/fon.09.91] [Cited by in Crossref: 218] [Cited by in F6Publishing: 197] [Article Influence: 19.8] [Reference Citation Analysis]
295 Zhang Z, Ma F, Zhou F, Chen Y, Wang X, Zhang H, Zhu Y, Bi J, Zhang Y. Functional polymorphisms of circadian negative feedback regulation genes are associated with clinical outcome in hepatocellular carcinoma patients receiving radical resection. Med Oncol 2014;31:179. [PMID: 25344870 DOI: 10.1007/s12032-014-0179-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
296 Song IH. Molecular targeting for treatment of advanced hepatocellular carcinoma. Korean J Hepatol 2009;15:299. [DOI: 10.3350/kjhep.2009.15.3.299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
297 Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics. 2008;5:45-60. [PMID: 18282123 DOI: 10.1586/14789450.5.1.45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
298 Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol. 2011;21:44-58. [PMID: 21182948 DOI: 10.1016/j.semcancer.2010.12.010] [Cited by in Crossref: 170] [Cited by in F6Publishing: 156] [Article Influence: 15.5] [Reference Citation Analysis]
299 Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194. [PMID: 19387255 DOI: 10.1097/mog.0b013e32832962a1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
300 Hoshida Y. Molecular Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2012;1:177-9. [PMID: 26213618 DOI: 10.1002/cld.117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
301 Amaro CP, Tam VC. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. Curr Oncol 2020;27:S173-80. [PMID: 33343211 DOI: 10.3747/co.27.7103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010;52:921-929. [PMID: 20385424 DOI: 10.1016/j.jhep.2009.12.034] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 10.9] [Reference Citation Analysis]
303 French SW. Molecular events in hepatic preneoplasia: a review. Exp Mol Pathol 2010;88:219-24. [PMID: 20097196 DOI: 10.1016/j.yexmp.2010.01.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
304 Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45-54. [PMID: 23938452 DOI: 10.1038/nrgastro.2013.143] [Cited by in Crossref: 185] [Cited by in F6Publishing: 155] [Article Influence: 23.1] [Reference Citation Analysis]
305 Ravi S, Singal AK. Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid. 2014;9:81-87. [PMID: 25114628 DOI: 10.2147/ce.s48626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
306 Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 42.5] [Reference Citation Analysis]
307 Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015;9:1628-1632. [PMID: 25789012 DOI: 10.3892/ol.2015.2960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
308 Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. [PMID: 28854942 DOI: 10.1186/s12943-017-0712-x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 101] [Article Influence: 29.3] [Reference Citation Analysis]
309 Bonel-Pérez GC, Pérez-Jiménez A, Gris-Cárdenas I, Parra-Pérez AM, Lupiáñez JA, Reyes-Zurita FJ, Siles E, Csuk R, Peragón J, Rufino-Palomares EE. Antiproliferative and Pro-Apoptotic Effect of Uvaol in Human Hepatocarcinoma HepG2 Cells by Affecting G0/G1 Cell Cycle Arrest, ROS Production and AKT/PI3K Signaling Pathway. Molecules 2020;25:E4254. [PMID: 32947962 DOI: 10.3390/molecules25184254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
310 Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147:1233-1247. [PMID: 22153071 DOI: 10.1016/j.cell.2011.10.043] [Cited by in Crossref: 331] [Cited by in F6Publishing: 319] [Article Influence: 36.8] [Reference Citation Analysis]
311 Segatelli V, de Oliveira EC, Boin IF, Ataide EC, Escanhoela CA. Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma. Hepatol Int 2014;8:260-5. [PMID: 26202507 DOI: 10.1007/s12072-014-9525-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
312 Scanga A, Kowdley K, Kowdley K, Mccaughan G, Trautwein C. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? Hepatology 2009;49:332-4. [DOI: 10.1002/hep.22756] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
313 Almhanna K, Philip PA. Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther 2009;2:261-7. [PMID: 20616913 DOI: 10.2147/ott.s5548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
314 Park SH, Lee SM, Kim YJ, Kim S. ChARM: Discovery of combinatorial chromatin modification patterns in hepatitis B virus X-transformed mouse liver cancer using association rule mining. BMC Bioinformatics 2016;17:452. [PMID: 28105934 DOI: 10.1186/s12859-016-1307-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
315 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
316 Freise C, Ruehl M, Seehofer D, Hoyer J, Somasundaram R. The inhibitor of Ca(2+)-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB. Invest New Drugs. 2013;31:452-457. [PMID: 23054207 DOI: 10.1007/s10637-012-9879-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
317 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51. [PMID: 20175032 DOI: 10.1055/s-0030-1247131] [Cited by in Crossref: 212] [Cited by in F6Publishing: 199] [Article Influence: 19.3] [Reference Citation Analysis]
318 Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S235-41. [PMID: 20547309 DOI: 10.1016/S1590-8658(10)60511-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
319 Evert M, Frau M, Tomasi ML, Latte G, Simile MM, Seddaiu MA, Zimmermann A, Ladu S, Staniscia T, Brozzetti S, Solinas G, Dombrowski F, Feo F, Pascale RM, Calvisi DF. Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value. Br J Cancer 2013;109:2654-64. [PMID: 24136149 DOI: 10.1038/bjc.2013.606] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
320 Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol. 2016;22:4034-4040. [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
321 Benod C, Carlsson J, Uthayaruban R, Hwang P, Irwin JJ, Doak AK, Shoichet BK, Sablin EP, Fletterick RJ. Structure-based discovery of antagonists of nuclear receptor LRH-1. J Biol Chem. 2013;288:19830-19844. [PMID: 23667258 DOI: 10.1074/jbc.m112.411686] [Cited by in Crossref: 71] [Cited by in F6Publishing: 35] [Article Influence: 8.9] [Reference Citation Analysis]
322 Chang TS, Chen CL, Wu YC, Liu JJ, Kuo YC, Lee KF, Lin SY, Lin SE, Tung SY, Kuo LM, Tsai YH, Huang YH. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma. PLoS One 2016;11:e0149897. [PMID: 26919045 DOI: 10.1371/journal.pone.0149897] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
323 Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34. [PMID: 20955973 DOI: 10.1016/j.bpg.2010.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
324 Xie QL, Liu Y, Zhu Y. Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver. Exp Ther Med 2016;12:59-68. [PMID: 27347018 DOI: 10.3892/etm.2016.3283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
325 Chen YJ, Wu H, Shen XZ. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. Cancer Lett 2016;379:245-52. [PMID: 26193663 DOI: 10.1016/j.canlet.2015.06.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
326 Zhang JY, Xu D, Liu ZZ, Li Y, Wang LJ, Xing BC. Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. Chin Med J (Engl) 2017;130:470-6. [PMID: 28218222 DOI: 10.4103/0366-6999.199839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
327 Pai RK, Wilcox R, Hart J. Molecular Gastrointestinal, Liver, and Pancreatic Pathology. Cell and Tissue Based Molecular Pathology. Elsevier; 2009. pp. 269-95. [DOI: 10.1016/b978-044306901-7.50028-6] [Reference Citation Analysis]
328 Chettiar ST, Malek R, Annadanam A, Nugent KM, Kato Y, Wang H, Cades JA, Taparra K, Belcaid Z, Ballew M, Manmiller S, Proia D, Lim M, Anders RA, Herman JM, Tran PT. Ganetespib radiosensitization for liver cancer therapy. Cancer Biol Ther 2016;17:457-66. [PMID: 26980196 DOI: 10.1080/15384047.2016.1156258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
329 Gao YB, Xiang ZL, Zhou LY, Wu ZF, Fan J, Zeng HY, Zeng ZC. Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone. J Cancer Res Clin Oncol 2013;139:669-79. [PMID: 23307318 DOI: 10.1007/s00432-012-1370-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
330 Fan Y, Hu D, Feng B, Wang W. The NQO1 C609T polymorphism and hepatocellular carcinoma risk. Tumour Biol 2014;35:7343-50. [PMID: 24532470 DOI: 10.1007/s13277-014-1712-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
331 Lee YC, Hur W, Choi JE, Piao LS, Hong SW, Bae SH, Choi JY, Yoon SK. Analysis of Gene Expression in Primary Hepatocellular Carcinoma Using Differentially Displayed Reverse Transcriptase Polymerase Chain Reaction. Korean J Gastroenterol 2009;53:361. [DOI: 10.4166/kjg.2009.53.6.361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
332 Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S264-S272. [PMID: 20547313 DOI: 10.1016/s1590-8658(10)60515-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
333 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
334 Mimeault M, Batra SK. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med 2014;39:3-32. [PMID: 23994756 DOI: 10.1016/j.mam.2013.08.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
335 Cabrera R. Systemic targeted therapy beyond sorafenib. Clin Liver Dis (Hoboken) 2012;1:212-6. [PMID: 31186890 DOI: 10.1002/cld.128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
336 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
337 Fang Y, Xue J, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012;55:1852-62. [DOI: 10.1002/hep.25576] [Cited by in Crossref: 288] [Cited by in F6Publishing: 271] [Article Influence: 32.0] [Reference Citation Analysis]
338 Shimizu M, Shirakami Y, Sakai H, Kubota M, Kochi T, Ideta T, Miyazaki T, Moriwaki H. Chemopreventive potential of green tea catechins in hepatocellular carcinoma. Int J Mol Sci 2015;16:6124-39. [PMID: 25789501 DOI: 10.3390/ijms16036124] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
339 Schaff Z, Kovalszky I, Lotz G, Kiss A. Hepatocellular carcinoma – from macroscopy to molecular pathology. Orvosi Hetilap 2010;151:982-9. [DOI: 10.1556/oh.2010.28875] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
340 Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, Zhang XF, Zhang HX, Zhou ZQ, Weng de S, Xia JC. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget 2016;7:16248-61. [PMID: 26919247 DOI: 10.18632/oncotarget.7637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
341 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
342 Bogaerts E, Heindryckx F, Vandewynckel YP, Van Grunsven LA, Van Vlierberghe H. The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol. 2014;44:1015-1022. [PMID: 24504124 DOI: 10.3892/ijo.2014.2286] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
343 Lu H, Chou F, Yeh K, Chang Y, Hsu NC, Chang J. Analysing the expression of protein kinase C eta in human hepatocellular carcinoma. Pathology 2009;41:626-9. [DOI: 10.3109/00313020903273076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
344 Lee J, Lee H, Yun S, Jung KH, Jeong Y, Yan HH, Hong S, Hong S. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma. Cancer Letters 2013;329:99-108. [DOI: 10.1016/j.canlet.2012.10.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]